Neuro-Bio welcomes Mark I. Butler as new COO Designate.
Mark holds a Ph.D. in Pharmacology from the University of Bristol, where he completed a “bench-to-bedside” thesis focusing on the mechanisms of new antiplatelet agents. He has over ten years experience managing wide ranging drug development programs in both academia and industry including running clinical trials and international target discovery programs.